Journal of Ophthalmology / 2019 / Article / Tab 3

Review Article

Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life

Table 3

Beta-blocker and quality of life.

QuestionnaireANOVA with Bonferroni post hoc

Ocular surface symptomsBaseline vs after 1 monthAfter 1 month vs after 3 months
Have you experienced any of the following during the last week: value value
(1) Eyes that are sensitive to light?0.0030.002
(2) Foreign body sensation?<0.0010.880
(3) Painful eye?<0.001<0.001
(4) Blurred vision?0.007<0.001
(5) Poor vision?0.208<0.001
(6) Ocular redness?<0.001<0.001
General symptoms
Have you experienced any of the following during the last week:
(7) Breathlessness at rest0.045<0.001
(8) Breathlessness after exercise0.083<0.001
(9) Fatigue, faintness0.0010.059
(10) Slow heart beat0.321<0.001
(11) Insomnia0.0380.279
(12) Headache0.251<0.001
Did you have any problems with your eyes that limited you in performing any of the following during the last week:
(13) Reading?<0.001<0.001
(14) Driving at night?0.0010.001
(15) Working with a computer?0.001<0.001
(16) Watching TV?0.001<0.001
Have your eyes felt uncomfortable in any of the following situations during the last week:
(17) Windy conditions ?<0.001<0.001
(18) Place or areas with low humidity (very dry)?<0.001<0.001
(19) Areas that are air-conditioned ?<0.001<0.001
During the last week:
(20) How do you assess the intensity of the ocular surface symptoms?<0.001<0.001
(21) Were you satisfied with the treatment?<0.001<0.001
(22) How many times did not you instill the eye drop?0.0060.001
(23) How was your quality of life related to treatment?<0.001<0.001

From [95].

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.